DexCom's growth rate has been accelerating for multiple quarters, and recently came in at around 22%. A rise in GLP-1 drugs has some investors concerned that DexCom's growth opportunities may be ...

We recently published an article titled 13 Best Internet of Things (IoT) Stocks to Buy Now. On February 13, Mizuho analyst Anthony Petrone raised the price target on DexCom, Inc. (NASDAQ:DXCM) to $90 ...

It's been a tough year for DexCom (NASDAQ: DXCM), whose stock price is down 25% since the start of 2025. It's a surprising performance, given that the overall stock market has been doing well; you ...

The average one-year price target for DexCom (XTRA:DC4) has been revised to 77,50 € / share. This is a decrease of 12.36% from the prior estimate of 88,43 € dated November 9, 2025. The price target is ...

DexCom, Inc.’s (NASDAQ:DXCM) third-quarter 2025 revenue reached $1.209 billion, beating the analyst consensus estimate of $1.179 billion. Revenue grew 22% year-over-year on a reported basis and 20% ...

DexCom (NASDAQ: DXCM) has outperformed the market over the past 10 years by 2.92% on an annualized basis producing an average annual return of 16.14%. Currently, DexCom has a market capitalization of ...

DexCom (NasdaqGS:DXCM) is seeing higher adoption of its continuous glucose monitoring systems among patients using GLP-1 drugs, as physicians pair both therapies for diabetes care. The company is ...

) has been revised to $88.30 / share. This is a decrease of 13.54% from the prior estimate of $102.13 dated November 7, 2025. The price target is an average of many targets provided by analysts. The ...

DexCom, Inc. (NASDAQ:DXCM) is one of the 10 best healthcare equipment stocks to buy according to hedge funds. On February 13, William Plovanic from Canaccord Genuity reduced the price target on DexCom ...

In February 2026, DexCom reported fourth-quarter 2025 sales of US$1,259.6 million and full-year 2025 sales of US$4,662 million, with net income rising to US$267.3 million for the quarter and US$836.3 ...